DK3077544T3 - Rationelt-baseret design af en målrettet terapi til cancer - Google Patents

Rationelt-baseret design af en målrettet terapi til cancer Download PDF

Info

Publication number
DK3077544T3
DK3077544T3 DK14867137.3T DK14867137T DK3077544T3 DK 3077544 T3 DK3077544 T3 DK 3077544T3 DK 14867137 T DK14867137 T DK 14867137T DK 3077544 T3 DK3077544 T3 DK 3077544T3
Authority
DK
Denmark
Prior art keywords
rational
cancer
targeted therapy
based design
design
Prior art date
Application number
DK14867137.3T
Other languages
English (en)
Inventor
David M Lu
Allen J Lee
Jason J Lee
Ruey-Min Lee
Original Assignee
Celestra Life Science Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celestra Life Science Llc filed Critical Celestra Life Science Llc
Application granted granted Critical
Publication of DK3077544T3 publication Critical patent/DK3077544T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
DK14867137.3T 2013-12-03 2014-12-03 Rationelt-baseret design af en målrettet terapi til cancer DK3077544T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361911423P 2013-12-03 2013-12-03
PCT/US2014/068373 WO2015084958A1 (en) 2013-12-03 2014-12-03 Rationale-based design of a targeted therapy for cancer

Publications (1)

Publication Number Publication Date
DK3077544T3 true DK3077544T3 (da) 2019-07-08

Family

ID=53274072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14867137.3T DK3077544T3 (da) 2013-12-03 2014-12-03 Rationelt-baseret design af en målrettet terapi til cancer

Country Status (9)

Country Link
US (2) US9782418B2 (da)
EP (1) EP3077544B1 (da)
CN (1) CN106029905B (da)
AU (1) AU2014360503A1 (da)
DK (1) DK3077544T3 (da)
ES (1) ES2732445T3 (da)
LT (1) LT3077544T (da)
PT (1) PT3077544T (da)
WO (1) WO2015084958A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3077544B1 (en) 2013-12-03 2019-04-24 Celestra Life Science LLC Rationale-based design of a targeted therapy for cancer
CN108220242A (zh) * 2016-12-10 2018-06-29 中国科学院大连化学物理研究所 Spop及突变体表达的c4-2稳定细胞系及构建方法
CN107299133A (zh) * 2017-06-09 2017-10-27 上海长海医院 一种前列腺癌的标志物spop及其在指导肿瘤治疗中的应用
CN110396544B (zh) * 2019-06-19 2021-12-24 山东大学齐鲁医院 Cul7在胶质瘤诊断、治疗和预后中的应用
WO2021007512A1 (en) * 2019-07-11 2021-01-14 Emory University Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (gr) binding agents, and/or hsp90 binding agents for uses in treating cancer
CN110970087B (zh) * 2019-12-31 2021-08-03 华中科技大学 一种鉴定调控细胞自噬的功能激酶的方法
CN111671760A (zh) * 2020-06-10 2020-09-18 谭志荣 人参皂苷ck在制备抗结直肠癌药物中的应用
EP4237096A1 (en) 2020-10-28 2023-09-06 Baylor College of Medicine Targeting of src-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489562B (zh) * 2006-07-21 2012-04-18 赛福伦公司 用于治疗脊髓增生病的jak抑制剂
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
GEP20125664B (en) * 2008-02-26 2012-10-10 Takeda Pharmaceuticals Co Condensed heterocyclic derivatives and application thereof
DE102008031699A1 (de) * 2008-07-04 2010-01-14 Protagen Ag Markersequenzen für Prostataentzündungserkrankungen, Prostatakarzinom und deren Verwendung
WO2010021822A2 (en) * 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
US20120282258A1 (en) * 2009-11-25 2012-11-08 Dana-Farber Cancer Institute, Inc. Crlf2 in precursor b-cell acute lymphoblastic leukemia
US9233163B2 (en) * 2010-12-28 2016-01-12 The Children's Hospital Of Philadelphia Hydrolytically releasable prodrugs for sustained release nanoparticle formulations
EP3077544B1 (en) 2013-12-03 2019-04-24 Celestra Life Science LLC Rationale-based design of a targeted therapy for cancer

Also Published As

Publication number Publication date
US20160303140A1 (en) 2016-10-20
PT3077544T (pt) 2019-08-01
ES2732445T3 (es) 2019-11-22
WO2015084958A1 (en) 2015-06-11
CN106029905A (zh) 2016-10-12
CN106029905B (zh) 2020-04-14
EP3077544A1 (en) 2016-10-12
US20180117061A1 (en) 2018-05-03
US9782418B2 (en) 2017-10-10
US10449202B2 (en) 2019-10-22
LT3077544T (lt) 2019-07-10
AU2014360503A1 (en) 2016-06-30
EP3077544A4 (en) 2017-07-05
EP3077544B1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK3046583T3 (da) Viruslignende partikelkonjugater til behandling af tumorer
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK2968208T3 (da) Behandling af kataplexi
DK3446742T3 (da) Lysterapienhed
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2961388T3 (da) Kombinationer af lægemidler
DK3021838T3 (da) Behandling af fedme
BR112015025408A8 (pt) combinações de drogas para tratar câncer
DK3079750T3 (da) Udskyllelige katetre
DK3077544T3 (da) Rationelt-baseret design af en målrettet terapi til cancer
DK2953904T3 (da) Fremgangsmåde til kontrolleret fremstilling af et biocid
DK3007726T3 (da) Fremgangsmåder til behandling af en tauopati
DK3089749T3 (da) Kombinerede præparater til behandling af cancer
DK2992104T3 (da) Fremgangsmåde til ekspression
DK3620198T3 (da) Udskyllelige katetre
DK2767269T3 (da) Terapeutisk anordning
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
UA29750S (uk) Інгалятор
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3052102T3 (da) Sammensætninger til behandling af cancere
DK3290035T3 (da) Procaspase-kombinationsterapi til behandling af cancer